

Tocilizumab-aazg

Date of approval: March 5, 2024

Indication: Rheumatoid Arthritis, Giant Cell Arteritis, Polyarticular Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis

MOA: Interleukin-6 (IL-6) receptor antagonist

Dosage form: Intravenous infusion or subcutaneous injection.

Denosumab-bbdz

Date of approval: March 5, 2024

Indication: Osteolytic Bone Lesions of Multiple Myeloma, Osteolytic Bone Metastases of Solid Tumors, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy, Osteoporosis

MOA: RANK ligand (RANKL) inhibitor

Dosage form: Subcutaneous injection.

Tislelizumab - jsgr

Date of approval: March 13, 2024

Indication: Metastatic esophageal squamous cell carcinoma

MOA: Humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody

Dosage form: Intravenous infusion.

Resmetirom

Date of approval: March 14, 2024

Indication: Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)

MOA: Thyroid hormone receptor-beta (THR-beta) agonist

Dosage form: Tablets

Atidarsagene autotemcel

Date of approval: March 18, 2024

Indication: Metachromatic leukodystrophy (MLD).

MOA: Autologous hematopoietic stem cell (HSC) gene therapy

Dosage form: Suspension for Intravenous Infusion

Aprocitentan

Date of approval: March 19, 2024

Indication: High Blood Pressure

MOA: Endothelin receptor antagonist (ERA)

Dosage form: Tablets

Givinostat

Date of approval: March 21, 2024

Indication: Duchenne muscular dystrophy

MOA: Givinostat is a histone deacetylase inhibitor

Dosage form: Oral Suspension

Macitentan and Tadalafil

Date of approval: March 22, 2024

Indication: Pulmonary Arterial Hypertension.

MOA: Endothelin receptor antagonist (ERA) and Phosphodiesterase 5 (PDE5) inhibitor

Dosage form: Tablets

Sotatercept

Date of approval: March 26, 2024

Indication: Pulmonary arterial hypertension

MOA: Activin signaling inhibitor

Dosage form: Subcutaneous injection.

Vadadustat

Date of approval: March 27, 2024

Indication: Anemia Due to Chronic Kidney Disease in adult patients on Dialysis

MOA: Hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor

Dosage form: Tablets

Danicopan

Date of approval: March 29, 2024

Indication: Paroxysmal Nocturnal Hemoglobinuria

MOA: Complement factor D inhibitor

Dosage form: Tablet

Risperidone

Date of approval: March 29, 2024

Indication: Schizophrenia in adults

MOA: Atypical antipsychotic

Dosage form: Extended-Release Intramuscular Injectable Suspension

Contact Details:

Email your suggestions to: hodpharmacology@kmchihsr.edu.in

Website: <http://www.kmchihsr.edu.in>